about
Tracking antigen-specific T-cells during clinical tolerance induction in humansNovel developments in the mechanisms of immune tolerance to allergensNon-infectious environmental antigens as a trigger for the initiation of an autoimmune skin disease.Towards defining molecular determinants recognized by adaptive immunity in allergic disease: an inventory of the available data.PeptX: using genetic algorithms to optimize peptides for MHC binding.In vitro evolution of allergy vaccine candidates, with maintained structure, but reduced B cell and T cell activation capacityAsthma-related comorbidities.Regulatory T cells in asthma.CD4+ CD25+ regulatory T cells: a therapeutic target for liver diseases.Allergy vaccines: dreams and reality.Latex allergy: a model for therapy.Effector and central memory T helper 2 cells respond differently to peptide immunotherapy.Novel immunotherapeutic approaches for allergy and asthma.Immunotherapy in asthma.Clinical immunology review series: an approach to desensitization.Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens.Mechanisms of immunotherapy to wasp and bee venom.Recombinant allergen immunotherapy: clinical evidence of efficacy--a review.Investigational drugs for the treatment of allergic rhinitis.Immunotherapy of type-1 allergies with virus-like particles and CpG-motifs.Investigational new drugs for allergic rhinitis.Allergen-specific immunotherapy of allergy and asthma: current and future trends.Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study.Epigenetic modification of the PD-1 (Pdcd1) promoter in effector CD4(+) T cells tolerized by peptide immunotherapy.Trends in Specific Immunotherapy for Allergic Rhinitis: A Survey of Chinese ENT Specialists.Is The Allergen Really Needed in Allergy Immunotherapy?Antigen-based immune therapeutics for type 1 diabetes: magic bullets or ordinary blanks?[Immunotherapy of allergic rhinitis without allergens? : new options for immunomodulation by vaccination with virus-like particles and CpG motifs].[Specific immunotherapy : clinical experience with recombinant molecular major allergens and hypoallergenic variants].Next generation immunotherapy for tree pollen allergies.A randomized, double-blind, placebo-controlled, dose-finding trial with Lolium perenne peptide immunotherapy.
P2860
Q24320083-8A9EF4BB-2C6D-4BA5-9E1C-C14BCEA9D306Q27025655-594A9D71-3AB2-48AE-8217-D1528166CF30Q30249078-82E390A7-5C9A-4DD6-AF2C-C7907753F2DBQ33846015-BE9D06D2-7564-4EBF-B1FE-66B78C2C664CQ33934654-57E08B51-84D1-476E-9FFC-E5CEEBA3DFB3Q34023674-410BC8C6-2055-4A5A-AA98-E8B5E1A13DB6Q34195201-B98AB1E6-A9F8-4119-BA38-34B4D95B0E2EQ36064548-9ED79C29-E801-4C9A-819E-667C31DFDCEDQ37082777-683C150C-B43D-47BC-89B5-704CF2B588BAQ37123463-40322C81-909B-420C-9FC4-C4A16181F7A4Q37171082-57187B17-DA0A-479E-9956-60103DFAAB8AQ37612747-7CC0541A-03BD-442D-B647-744268A19670Q37728000-A331587C-9A39-49E9-A4F9-CD1B025F834DQ37793242-887DD56D-5CB1-44F9-A70D-5B73790A895AQ37822834-AAF10C47-C419-494A-A812-279C0083EAB3Q37847222-CF2404BA-3EBC-4A65-9562-7E88AB71B911Q37897667-A23CA959-21A6-4AE0-B044-1CD21B30060EQ38112352-1F7A05A9-CAE1-411F-8505-8F0E3C424E0CQ38202695-70D6899A-C908-46E8-BA79-FC3AD1FE0008Q38217708-E767CB85-635D-4818-84A3-23C07148686AQ39111947-67EBF468-1087-41FA-8974-DA4368CEED52Q40006542-9B941F30-B215-4C17-A58E-1ADD77E5C631Q40023867-2DFAB339-700E-4C7D-86E6-8907D3383594Q42027896-361D31CB-E11F-47FA-A4D8-E667CF1251E6Q42716940-3EA92555-5086-4017-B06D-96596E9664B1Q42730811-EDF5D890-05AE-4F92-943D-62F22E32DBB2Q42739489-72956276-772C-4C66-8AE1-4DD4650295ACQ43962396-A82BB0E0-DC51-4047-A501-47C0D3871137Q44500848-A8EC9974-BE62-44F0-A1EC-3714182C414BQ47884083-42C55DF2-D24E-4A15-935D-F26BC090E65BQ48278642-94181FB2-FBBF-4C9C-96E0-9B8C5265F799
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Update on the current status of peptide immunotherapy.
@en
type
label
Update on the current status of peptide immunotherapy.
@en
prefLabel
Update on the current status of peptide immunotherapy.
@en
P1476
Update on the current status of peptide immunotherapy.
@en
P2093
Mark Larché
P304
P356
10.1016/J.JACI.2007.02.015
P407
P577
2007-04-01T00:00:00Z